Literature DB >> 9021209

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.

J H Jorgensen1, M L McElmeel, C W Trippy.   

Abstract

U-100592 and U-100766 are closely related antibiotics of the oxazolidinone class. Their in vitro activities were determined against 100 isolates of Staphylococcus aureus and 100 isolates of coagulase-negative Staphylococcus species by broth and agar dilution test methods. The MICs of both compounds by either test method at which 50 and 90% of isolates are inhibited were 2 and 4 micrograms/ml, respectively, for S. aureus and 1 to 2 micrograms/ml for coagulase-negative staphylococci. Time-kill assay with selected strains indicated a primarily bacteriostatic effect against staphylococci.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021209      PMCID: PMC163731     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

Review 2.  Epidemiology of drug resistance: implications for a post-antimicrobial era.

Authors:  M L Cohen
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

3.  Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

Authors:  D C Eustice; P A Feldman; I Zajac; A M Slee
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

4.  In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.

Authors:  A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.

Authors:  A Tomasz
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

6.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

7.  In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

9.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  9 in total
  13 in total

1.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci.

Authors:  Fred C Tenover; Portia P Williams; Sheila Stocker; Angela Thompson; Leigh Ann Clark; Brandi Limbago; Roberta B Carey; Susan M Poppe; Dean Shinabarger; John E McGowan
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

Review 3.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study.

Authors:  Suzan Sacar; Mustafa Sacar; Ilknur Kaleli; Semra Toprak; Nural Cevahir; Zafer Teke; Ali Asan; Barbaros Sahin; Ahmet Baltalarli; Huseyin Turgut
Journal:  Curr Ther Res Clin Exp       Date:  2007-01

5.  Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.

Authors:  E J Goldstein; D M Citron; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Authors:  Daniela Baldoni; Manuel Haschke; Zarko Rajacic; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 7.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

8.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11

Review 9.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.

Authors:  Patrick Grohs; Marie-Dominique Kitzis; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.